Cargando…

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients

Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stein, Shayna, Zhao, Rui, Haeno, Hiroshi, Vivanco, Igor, Michor, Franziska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766249/ https://www.ncbi.nlm.nih.gov/pubmed/29293494 http://dx.doi.org/10.1371/journal.pcbi.1005924

Ejemplares similares

Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
por: Cheng, Yu-Chen, et al.
Publicado: (2023)

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability
por: Iwami, Shingo, et al.
Publicado: (2012)

Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies
por: Yamamoto, Kimiyo N., et al.
Publicado: (2019)

The Probable Cell of Origin of NF1- and PDGF-Driven Glioblastomas
por: Hambardzumyan, Dolores, et al.
Publicado: (2011)

Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies
por: Altrock, Philipp M., et al.
Publicado: (2018)

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015)

Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma
por: Randles, Amanda, et al.
Publicado: (2021)

Stochastic Tunneling of Two Mutations in a Population of Cancer Cells
por: Haeno, Hiroshi, et al.
Publicado: (2013)

Mathematical analysis identifies the optimal treatment strategy for epidermal growth factor receptor-mutated non-small cell lung cancer
por: Yu, Qian, et al.
Publicado: (2023)

Mathematical Modeling of Locoregional Recurrence Caused by Premalignant Lesions Formed Before Initial Treatment
por: Takaki, Mitsuaki, et al.
Publicado: (2021)

Different chemical proteomic approaches to identify the targets of lapatinib
por: Kovačević, Tatjana, et al.
Publicado: (2023)

Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
por: Gamucci, T., et al.
Publicado: (2013)

Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma
por: Fisher, Carl, et al.
Publicado: (2019)

Optimum investment strategy in the power industry: mathematical models
por: Bartnik, Ryszard, et al.
Publicado: (2016)

Tight upper bounds for semi-online scheduling on two uniform machines with known optimum
por: Dósa, György, et al.
Publicado: (2017)

Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity
por: Dean, Jamie A, et al.
Publicado: (2022)

O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
por: Leucht, Stefan, et al.
Publicado: (2018)

Colchicine in acute gouty arthritis: the optimum dose?
por: Varughese, George I, et al.
Publicado: (2006)

Patterns of Proliferative Activity in the Colonic Crypt Determine Crypt Stability and Rates of Somatic Evolution
por: Zhao, Rui, et al.
Publicado: (2013)

Computational modeling of locoregional recurrence with spatial structure identifies tissue-specific carcinogenic profiles
por: Abubakar, Sharafudeen Dahiru, et al.
Publicado: (2023)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
por: Sherrill, B, et al.
Publicado: (2008)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

Mathematical models of targeted cancer therapy
por: Abbott, L H, et al.
Publicado: (2006)

Mathematical programming and financial objectives for scheduling projects
por: Kimms, Alf
Publicado: (2001)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
por: Rios, Adan, et al.
Publicado: (2016)

Lapatinib for the treatment of breast cancer in the People’s Republic of China
por: Wang, Hongjiang
Publicado: (2014)

OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
por: Perez Chacon, Gladymar, et al.
Publicado: (2020)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
por: Totterdell, James A., et al.
Publicado: (2022)

An Optimum Population
Publicado: (1919)

Mathematic Modeling for Optimum Conditions on Aflatoxin B(1) Degradation by the Aerobic Bacterium Rhodococcus erythropolis
por: Kong, Qing, et al.
Publicado: (2012)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Development of the Rat Model of Lapatinib-Induced Diarrhoea
por: Bowen, Joanne M.
Publicado: (2014)

Lapatinib-induced acute generalized exanthematous pustulosis
por: Lakshmi, Chembolli, et al.
Publicado: (2010)

The concomitant use of lapatinib and paracetamol - the risk of interaction
por: Karbownik, Agnieszka, et al.
Publicado: (2018)

Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib
por: Foo, Jasmine, et al.
Publicado: (2009)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5cp58001ed09i9e1j6cae09dtk